生物医药ETF（512290）连续3日迎资金净流入，CXO市场关注度提升

Group 1 - The CXO market is experiencing a resurgence in attention due to the recovery of domestic CRO demand and the release of short-term emotional suppression, with a trend of increasing volume and price for domestic CRO orders since 2025 [1] - Several CROs are accelerating new order signings quarterly, benefiting from the overseas expansion of innovative drug business development and stable financing, leading to double-digit growth in project volume [1] - There is a positive outlook for CRO performance entering an improvement cycle in 2026, supported by strong customer demand and rising prices for experimental monkeys, safety evaluation quotes, and clinical project pricing since Q4 [1] Group 2 - The global CDMO orders are robust, with a strong certainty of high growth in performance, particularly in the small molecule CDMO sector, which is seeing steady order growth [1] - New molecular fields such as ADC, peptides, and bispecific antibodies are experiencing rapid order increases, with more late-stage clinical and commercialization projects expected to ramp up [1] - The domestic and international biopharmaceutical primary market is showing signs of recovery in investment and financing, with potential further boosts from the Federal Reserve's interest rate cuts [1] Group 3 - The biopharmaceutical ETF (512290) tracks the CS Biomedicine Index (930726), which selects listed companies involved in biotechnology, pharmaceuticals, and medical devices from the Shanghai and Shenzhen markets [2] - The CS Biomedicine Index focuses on innovation and development in the biopharmaceutical industry, comprising companies with strong competitiveness in R&D, production, and sales, reflecting market dynamics and trends in China's biopharmaceutical sector [2]